Skip to main content
In Memoriam: David J. Galas, Ph.D. (1944-2023) >>
Hide alert
About Us
History & Overview
Our Team
Research Services
Venture Analysts
Venture Center
Our Partners
Grants
Accelerating Innovation
Technology Commercialization
Postdoctoral Fellowships
Student Programs
Building the Innovation Ecosystem
Submit Phased Grant Pre-Proposal
Recent Grants
Startup Investments
Investing in Washington
Active Portfolio & Exits
Stories
News
Articles
Videos
Reports
Contact
Close
Keywords:
Search
Toggle Search
Toggle mobile menu
Seattle-based Icosavax, which is developing COVID-19 vaccines, files for IPO 4 years after launch
Post navigation
←
Anindya Roy receives $250,000 from Washington Research Foundation to develop inhaled protein therapeutic for IPF
Absci’s IPO reflects booming biotech market and growing PNW life sciences industry
→
Comments are closed.
About Us
History & Overview
Our Team
Research Services
Venture Analysts
Venture Center
Our Partners
Grants
Accelerating Innovation
Technology Commercialization
Postdoctoral Fellowships
Student Programs
Building the Innovation Ecosystem
Submit Phased Grant Pre-Proposal
Recent Grants
Startup Investments
Investing in Washington
Active Portfolio & Exits
Stories
News
Articles
Videos
Reports
Contact
Close menu
